Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines

Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines

The lack of validated immunological correlates of protection makes tuberculosis vaccine development difficult and expensive. Using intradermal bacille Calmette-Guréin (BCG) as a surrogate for aerosol Mycobacterium tuberculosis (M.tb) in a controlled human infection model could facilitate vaccine dev...

Bibliografske podrobnosti
Main Authors:	Harris, S, White, A, Stockdale, L, Tanner, R, Sibley, L, Sarfas, C, Meyer, J, Peter, J, O'Shea, M, Manjaly Thomas, Z, Hamidi, A, Satti, I, Dennis, M, McShane, H, Sharpe, S
Format:	Journal article
Izdano:	Elsevier 2017

Podobne knjige/članki

A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates
od: Tanner, R, et al.
Izdano: (2021)

Optimisation of a human BCG challenge model
od: Wilkie, M, et al.
Izdano: (2015)

MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates
od: Peralta-Álvarez, MP, et al.
Izdano: (2024)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
od: Harris, S, et al.
Izdano: (2013)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination.
od: Harris, SA, et al.
Izdano: (2014)

MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates
od: Marco Polo Peralta-Álvarez, et al.
Izdano: (2024-11-01)

The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells
od: Tanner, R, et al.
Izdano: (2021)

A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates
od: Rachel Tanner, et al.
Izdano: (2021-01-01)

Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates
od: Alvarez, MPP, et al.
Izdano: (2024)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
od: Minhinnick, A, et al.
Izdano: (2016)

Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates
od: Marco Polo Peralta Alvarez, et al.
Izdano: (2024-05-01)

The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells [version 1; peer review: 2 approved]
od: Rachel Tanner, et al.
Izdano: (2021-03-01)

The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells [version 2; peer review: 2 approved]
od: Rachel Tanner, et al.
Izdano: (2021-09-01)

Gene expression and cytokine profile correlate with mycobacterial growth in a human BCG challenge model
od: Matsumiya, M, et al.
Izdano: (2014)

Immune cell population dynamics following neonatal BCG vaccination and aerosol BCG revaccination in rhesus macaques
od: Laura Sibley, et al.
Izdano: (2024-07-01)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
od: Sheehan, S, et al.
Izdano: (2015)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
od: Satti, I, et al.
Izdano: (2014)

Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates
od: Andrew D. White, et al.
Izdano: (2023-10-01)

Development of a primate model for tuberculosis vaccine research: IFN-gamma responses induced by BCG vaccination and M-tuberculosis infection in macaques
od: Dowall, S, et al.
Izdano: (2007)

Induction of functional specific antibodies, IgG-secreting plasmablasts and memory B cells following BCG vaccination
od: Bitencourt, J, et al.
Izdano: (2021)

IV BCG Vaccination and Aerosol BCG Revaccination Induce Mycobacteria-Responsive γδ T Cells Associated with Protective Efficacy against <i>M. tb</i> Challenge
od: Alexandra L. Morrison, et al.
Izdano: (2023-10-01)

T-cell activation is an immune correlate of risk in BCG vaccinated infants
od: Fletcher, H, et al.
Izdano: (2016)

Predicting IFN-γ responses after BCG vaccination in humans from macaques: A proof-of-concept study of Immunostimulation/Immunodynamic modelling methods
od: Rhodes, S, et al.
Izdano: (2017)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
od: Harris, S, et al.
Izdano: (2011)

Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants.
od: Fletcher, H, et al.
Izdano: (2016)

Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG.
od: Fletcher, H, et al.
Izdano: (2013)

Development of a BCG challenge model for the testing of vaccine candidates against tuberculosis in cattle
od: Villarreal-Ramos, B, et al.
Izdano: (2017)

Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A
od: Harris, SA, et al.
Izdano: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
od: Satti, I, et al.
Izdano: (2014)

Characterization of the Infant Immune System and the Influence and Immunogenicity of BCG Vaccination in Infant and Adult Rhesus Macaques
od: Charlotte Sarfas, et al.
Izdano: (2021-10-01)

The humoral immune response to BCG vaccination
od: Tanner, R, et al.
Izdano: (2019)

Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection
od: O'Shea, M, et al.
Izdano: (2018)

Revaccination with BCG: does it work?
od: McShane, H
Izdano: (2024)

Understanding BCG is the key to improving it.
od: McShane, H
Izdano: (2013)

Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination
od: Julia Bitencourt, et al.
Izdano: (2022-01-01)

T-cell activation is an immune correlate of risk in BCG vaccinated infants
od: Helen A. Fletcher, et al.
Izdano: (2016-04-01)

Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants
od: Satti, I, et al.
Izdano: (2022)

Optimization of a human bacille Calmette-Guerin challenge model: a tool to evaluate antimycobacterial immunity
od: Minhinnick, A, et al.
Izdano: (2015)

Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
od: Minassian, A, et al.
Izdano: (2011)

TB and SIV Coinfection; a Model for Evaluating Vaccine Strategies against TB Reactivation in Asian Origin Cynomolgus Macaques: A Pilot Study Using BCG Vaccination
od: Andrew D. White, et al.
Izdano: (2021-08-01)